Sichuan Qingmu Pharmaceutical is an API manufacturer based in China. It holds 11 active US drug master files across a filed portfolio of 11 molecules. Its GMP standing is certified by MFDS (Korea). Its most recent recorded inspection, by US FDA, closed on 7 September 2021 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3014747858 |
| Molecule | Regulators | Docs |
|---|---|---|
| Dabigatran Etexilate | US FDA | 1 |
| Lemborexant | US FDA | 1 |
| Lenvatinib | US FDA | 1 |
| Methylene Blue | US FDA | 1 |
| Nalmefene | US FDA | 1 |
| Naloxone | US FDA | 1 |
| Nicardipine | US FDA | 1 |
| Rotigotine | US FDA | 1 |
| Silodosin | US FDA | 1 |
| Sugammadex | US FDA | 1 |
| Ticagrelor | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MFDS (Korea) | None | 2 |
Choose your molecules and target markets. Sichuan Qingmu Pharmaceutical comes back tiered against every other supplier able to file there.
Start for free